Viraleze antiviral nasal spray shows protection against SARS-CoV-2 Omicron in viral challenge model July 20, 2022
Lumos Diagnostics sees stock plummet 65% on FDA rejection of Febridx 510(k) July 15, 2022 By Tamra Sami Rapid point-of-care (POC) diagnostics company Lumos Diagnostics Holdings Pty. Ltd. saw its stock plummet 65% on the news that the U.S. FDA rejected its Febridx 510(k) because the device was not substantially equivalent to the predicate device.Read More
A new series of broad-spectrum bacterial type II topoisomerase inhibitors: synthesis and evaluation July 14, 2022
iNtRON Biotechnology reports efficacy of CDL-200 against clinical isolates from CDI patients July 12, 2022
RSS